The Impact of Treatment with Guselkumab on Skin-related Quality of Life in Male and Female Patients with Moderate to Severe Psoriasis: Results from the VOYAGE 1 and 2 Trials

被引：0
|
作者：
Armstrong, April [1 ]
Puig, Luis [2 ]
Papp, Kim A. [3 ]
Strauss, Marcie E. [4 ]
Yang, Ya-Wen [5 ]
Cheng, Ru-Fong [6 ]
Miller, Megan [7 ]
Murase, Jenny E. [8 ,9 ]
Fernandez-Penas, Pablo [10 ]
Han, Chenglong [11 ]
机构：
[1] Univ Southern Calif, Keck Sch Med, Los Angeles, CA USA
[2] Autonomous Univ Barcelona, Hosp Santa Creu & Sant Pau, Barcelona, Spain
[3] K Papp Clin Res & Prob Res Inc, Waterloo, ON, Canada
[4] MEDASOURCE, Indianapolis, IN USA
[5] Janssen Pharmaceut Co Johnson & Johnson, Immunol Global Med Affairs, Horsham, PA USA
[6] Johnson & Johnson, Womens Hlth, Chief Med Off, New Brunswick, NJ USA
[7] Janssen Res & Dev LLC, Spring House, PA USA
[8] Univ Calif San Francisco, San Francisco, CA USA
[9] Palo Alto Fdn Med Grp, Mountain View, CA USA
[10] Westmead Hosp, Sydney Med Sch, Dept Dermatol, Westmead, NSW, Australia
[11] Janssen Global Serv LLC, Malvern, PA USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2023年 / 89卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：AB235 / AB235
页数：1
相关论文
共 50 条
  • [41] Efficacy of guselkumab in patients with moderate-to-severe plaque psoriasis with involvement of the scalp, nails, hands, and feet: Results from the phase 3 VOYAGE 2 study
    Reich, Kristian
    Armstrong, April W.
    Foley, Peter
    Song, Michael
    Wasfi, Yasmine
    Randazzo, Bruce
    Shen, Yaung-Kaung
    Gordon, Kenneth B.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB120 - AB120
  • [42] Consistent responses with guselkumab treatment in Asian and non-Asian patients with psoriasis: An analysis from VOYAGE 1 and VOYAGE 2
    Reich, Kristian
    Song, Michael
    Li, Shu
    Jiang, Jingzhi
    Youn, Sang Woong
    Tsai, Tsen-Fang
    Choe, Yong Beom
    Huang, Yu-Huei
    Gordon, Kenneth B.
    JOURNAL OF DERMATOLOGY, 2019, 46 (12): : 1141 - 1152
  • [43] Efficacy responses across disease severity and treatment history subgroups of patients with moderate to severe plaque psoriasis treated with guselkumab: Pooled results from VOYAGE 1&2 through 5 years
    Gordon, Kenneth B.
    Merola, Joseph F.
    Foley, Peter
    Choi, Olivia
    Chan, Daphne
    Miller, Megan
    You, Yin
    Shen, Yaung-Kaung
    Yang, Ya-Wen
    Blauvelt, Andrew
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB163 - AB163
  • [44] Patient-reported symptoms and signs of moderate-to-severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trial
    Papp, K. A.
    Blauvelt, A.
    Kimball, A. B.
    Han, C.
    Randazzo, B.
    Wasfi, Y.
    Shen, Y. -K.
    Li, S.
    Griffiths, C. E. M.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2018, 32 (09) : 1515 - 1522
  • [45] Anxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study
    Gordon, K. B.
    Armstrong, A. W.
    Han, C.
    Foley, P.
    Song, M.
    Wasfi, Y.
    You, Y.
    Shen, Y. -K.
    Reich, K.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2018, 32 (11) : 1940 - 1949
  • [46] Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial
    Lebwohl, M.
    Papp, K.
    Han, C.
    Schenkel, B.
    Yeilding, N.
    Wang, Y.
    Krueger, G. G.
    BRITISH JOURNAL OF DERMATOLOGY, 2010, 162 (01) : 137 - 146
  • [47] Risankizumab for the Treatment of Moderate to Severe Psoriasis: Impact on Health-Related Quality of Life and Psychological Wellbeing
    Gracia-Cazana, Tamara
    Bernal-Masferrer, Laura
    Morales-Callaghan, Ana Maria
    Almenara-Blasco, Manuel
    Gilaberte, Yolanda
    CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY, 2023, 16 : 221 - 229
  • [48] SPEED OF RESPONSE OF GUSELKUMAB COMPARED WITH ADALIMUMAB FOR THE TREATMENT OF MODERATE-TO-SEVERE PSORIASIS: RESULTS THROUGH WEEK 24 FROM THE PHASE 3, DOUBLE-BLINDED, PLACEBO- AND ACTIVE COMPARATOR-CONTROLLED VOYAGE 1 AND VOYAGE 2 TRIALS
    Blauvelt, Andrew
    Tyring, Stephen
    Philipp, Sandra
    Adam, David
    Song, Michael
    Wasfi, Yasmine
    You, Yin
    Shen, Yaung-Kaung
    Bagel, Jerry
    ACTA DERMATO-VENEREOLOGICA, 2018, 98 : 21 - 21
  • [49] Frequency of gastrointestinal-related serious adverse events among guselkumab-treated patients with moderate to severe psoriasis: A pooled analysis of Voyage 1 and Voyage 2 through 3 years
    Foley, Peter
    Reich, Kristian
    Blauvelt, Andrew
    Bagel, Jerry
    Langley, Richard
    Song, Michael
    Ramachandran, Paraneedharan
    Shen, Yaung-Kaung
    You, Yin
    Lebwohl, Mark
    Griffiths, Christopher E. M.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB35 - AB35
  • [50] Speed of response of guselkumab compared with adalimumab for the treatment of moderate-to-severe psoriasis: Results through week 24 from the phase 3, double-blinded, placebo- and active comparator-controlled VOYAGE 1 and VOYAGE 2 trials
    Blauvelt, Andrea
    Tyring, Stephen
    Philipp, Sandra
    Adam, David
    Song, Michael
    Wasfi, Yasmine
    You, Yin
    Shen, Yaung-Kaung
    Bagel, Jerry
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB267 - AB267
12345